Zelira Therapeutics Limited (ASX:ZLD)
0.5000
0.00 (0.00%)
Feb 27, 2026, 3:55 PM AEST
Zelira Therapeutics Revenue
In the fiscal year ending June 30, 2025, Zelira Therapeutics had annual revenue of 656.00 AUD, down -99.31%. Zelira Therapeutics had revenue of 1.00 in the half year ending June 30, 2025, a decrease of -100.00%.
Revenue
656.00
Revenue Growth
-99.31%
P/S Ratio
9,067.95
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 656.00 | -94.30K | -99.31% |
| Jun 30, 2024 | 94.95K | -206.17K | -68.47% |
| Jun 30, 2023 | 301.12K | -1.24M | -80.45% |
| Jun 30, 2022 | 1.54M | 877.31K | 132.26% |
| Jun 30, 2021 | 663.32K | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 9.75M |
| Immuron | 7.48M |
| Tissue Repair | 3.38M |
| Acrux | 2.81M |
| Nexalis Therapeutics | 761.96K |
| Anatara Lifesciences | 623.76K |
| AdAlta | 608.07K |
| Bio-Gene Technology | 390.63K |